Swiss Drug Pricing Under US Most-Favored-Nation Pressure: Confidential Rebates and a Pending Ordinance

A US pricing team works with two ledgers: the published price and the price after rebates. Federal law generally protects information reported under the Medicaid drug-rebate provisions from disclosure identifying a manufacturer or its drug prices, subject to statutory exceptions.142 U.S.C. § 1396r-8(b)(3)(D), confidentiality of information reported under the Medicaid drug-rebate provisions, subject to the specified scope and exceptions. Switzerland is developing its statutory basis for confidential refunds on prices in the national reimbursement list, the SL. Parliament adopted the relevant KVG amendments on 21 March 2025, but the medicines provisions were not in force on 3 September 2026. US most-favored-nation policy has added a further question to negotiations with the Swiss Federal Office of Public Health (BAG): depending on the product and the manufacturer's commitments or model participation, a Swiss price may affect a US obligation or benchmark. Executive Order 14297 initiated agency action; the agreements described by the White House and the public pricing models do not operate on identical terms.2Executive Order 14297 of May 12, 2025, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, 90 Fed. Reg. 20749 (May 15, 2025), sections 3, 5(a)–(b) and 6(b). Both Swiss parliamentary health committees had asked the Federal Council to wait before adopting most of the implementing amendments. Interpharma reported that, in an anonymized member survey covering January 2025 to June 2026, seven of twenty-two new innovative medicines had not been submitted for the SL because of the MFN regime; three had also not been submitted to Swissmedic.3Interpharma, “Press release: One in three new innovative medicines not submitted for reimbursement by health insurance companies” (13 August 2026): an anonymized and aggregated member survey reported seven of 22 new innovative medicines not submitted for the Spezialitätenliste between January 2025 and June 2026 because of the US most-favored-nation regime, three also not submitted to Swissmedic. The release attributes the decisions to that regime and warns of a two-tier system; it does not publish the underlying medicine-level dataset. The decision whether, when and on what terms to seek Swiss reimbursement can therefore have consequences beyond the Swiss market.

1. A Statute Adopted, an Ordinance Pending: Where Swiss Confidential Pricing Stands

Switzerland is not a member of the European Union, and its pricing of reimbursed medicines is a national administrative procedure. A medicine enters the SL on the application of the holder of its Swissmedic authorization. In the ordinary pricing method, the BAG gives equal weight to a therapeutic comparison and the average foreign-price comparison under Art. 65b KVV. Art. 34abis KLV names nine reference countries and permits additional comparable countries in specified circumstances; Art. 65d KVV provides for review every three years.4Verordnung über die Krankenversicherung (KVV) vom 27. Juni 1995 (SR 832.102), Stand am 1. August 2026, Art. 65b KVV, Art. 65d KVV, Art. 71(1)(b) KVV and Art. 71a KVV to Art. 71d KVV. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung (Krankenpflege-Leistungsverordnung, KLV) vom 29. September 1995 (SR 832.112.31), Stand am 1. August 2026, Art. 34abis KLV and Art. 38b KLV to Art. 38g KLV (reference countries and single-case reimbursement conditions, discounts and exceptions). The mechanics, and their implications for Swiss research, are examined in the analysis of Swiss pharmaceutical pricing. What matters here is narrower. The listed price is public, while confidential refunds have developed in administrative practice. Art. 71(1)(b) KVV excludes their calculation bases from proactive publication. That exception does not itself resolve a request for access to the underlying refund information under the Swiss freedom-of-information statute.

On 21 March 2025 the Federal Assembly adopted the second cost-containment package, the Kostendämpfungspaket 2, and with it, among many other changes, four new provisions on medicines in the Swiss health insurance statute, the KVG.5Bundesgesetz über die Krankenversicherung (KVG) vom 18. März 1994 (SR 832.10), Stand am 1. Juli 2026, Art. 32 KVG and Art. 52 KVG; Bundesgesetz über die Krankenversicherung (KVG) (Massnahmen zur Kostendämpfung – Paket 2), Änderung vom 21. März 2025, BBl 2025 1108, AS 2026 294, Art. 52b KVG to Art. 52e KVG as adopted, transitional provisions III(4)–(5), III(8) and section V of that KVG amendment, and its commencement notice of 5 June 2026. The new medicines provisions were not in force at 3 September 2026. Art. 52b KVG allows the BAG, by way of exception and only so far as necessary to comply with the requirement in Art. 32 KVG that reimbursed services be effective, appropriate and economical, to oblige the holder to refund part of the price or of the costs to the insurer or to a new refund fund. Art. 52c KVG lets the Federal Council provide that information on the amount, calculation or modalities of those refunds may not be made accessible to third parties, in which case the authority refuses access under the Swiss freedom-of-information statute, the BGÖ. Art. 52d KVG permits provisional listing from authorization for qualifying medicines or new indications with demonstrated high medical need and accelerated Swissmedic status, on the designated holder's application and after consultation of the competent commission. It requires a decision on any application for definitive listing within twenty-four months of provisional inclusion. Art. 52e KVG allows the BAG to require an appropriate turnover refund for a medicine with a large Swiss market volume, taking account of existing quantity or turnover conditions, supply security, product-specific manufacturing and distribution circumstances and the number of reimbursed indications. The referendum period lapsed unused on 10 July 2025. On 5 June 2026 the Federal Council brought provisions on electronic invoicing and on targeted information for insured persons into force on 1 July 2026 and left the rest, the four medicines provisions among them, for a later date. Art. 52b KVG to Art. 52e KVG were adopted on 21 March 2025 and were not in force on 3 September 2026.

The ordinance that would operate those provisions went to consultation on 18 February 2026, with a deadline of 26 May 2026.6Eidgenössisches Departement des Innern (EDI), 'Änderung der Verordnung über die Krankenversicherung (KVV) und der Krankenpflege-Leistungsverordnung (KLV) (Umsetzung des Kostendämpfungspakets 2 im Arzneimittelbereich)', Vernehmlassungsverfahren, BBl 2026 367 (consultation 18 February–26 May 2026), with draft KVV, Art. 65b KVV, Art. 65bquater KVV to Art. 65bocties KVV and VII(1)–(2) of the draft KVV; draft KLV, Art. 34cter KLV; Bundesamt für Gesundheit, Erläuternder Bericht zur Eröffnung des Vernehmlassungsverfahrens on those amendments (18 February 2026) 7–8, 17, 21–22 and 28. Proposed rules only: VII(1) covers proceedings pending at commencement; VII(2) separately addresses already-listed products. It is more than an implementing text, because it also rewrites how prices are set. The foreign-price comparison would move from the average of the reference-country prices to their median under Art. 65b(2)(b) of the draft KVV. Where listing cannot otherwise be secured, the BAG could, in agreement with the holder, publish an ex-factory price above the price it has determined and collect the difference as a refund under Art. 65b(3sexies) of the draft KVV. Confidentiality would be conditional. Under Art. 65bsexies of the draft KVV the BAG may, on the holder's application, order that information on the amount, calculation or modalities of a refund is not made accessible to third parties for six years from listing of the medicine or indication, notably on a price difference exceeding 25 percent under the draft criterion or payment into the fund. The order would be reviewed regularly and could be extended only exceptionally. The order is excluded where a country in the Swiss foreign-price comparison has a lower price than the Swiss price after refund. Even where it is granted, the BAG may disclose the price determined by the ordinary method, which is the net figure, to other holders for their own therapeutic cross-comparisons, and they must keep it confidential.

The cost-consequence model under Art. 65bsepties of the draft KVV would require refunds for products within its scope once qualifying reimbursed turnover exceeds a basic CHF 15 million threshold. It covers compulsory health insurance and invalidity insurance turnover, calculated net of refunds, with specified exclusions and adjustments. The threshold rises by CHF 2 million for each additional relevant indication, to at most CHF 50 million; relevance is defined by comparison with the main indication, not simply by the existence of another authorization. The proposal also aggregates qualifying products across group companies and provides conditional reductions or exemptions. Refunds are computed in marginal CHF 5 million bands: the draft KLV starts at 15 percent for the CHF 15–20 million band and reaches 40 percent above CHF 70 million, subject to the overall 40 percent ceiling. The explanatory report anticipated commencement in early 2027, described the rates as provisional and projected about CHF 350 million in annual savings from this model in 2029. These were proposal-stage projections, not an adopted commencement date.6

Proposed Swiss confidentiality could conceal refund information from public access without settling its treatment under a US pricing commitment. The Swiss eligibility test and the separate US price-data rules do not use one uniform benchmark.

By early September 2026 the draft had not been adopted. On 21 August 2026 the National Council's health committee (SGK-N) recommended, by 16 votes to 9, that the Federal Council hold back most of the amendments implementing the volume rebates and the other new medicines measures, rework them fundamentally once a working group on the life-sciences location had reported, and design them to be compatible with what the committee called the planned US reference-price system (das geplante Referenzpreissystem der USA) while securing access to new therapies.7Kommission für soziale Sicherheit und Gesundheit des Nationalrates (SGK-N), 'Elektronisches Gesundheitsdossier: Geordneten Übergang vom EPD zu E-GD sicherstellen' (21 August 2026), medicine section; Kommission für soziale Sicherheit und Gesundheit des Ständerates (SGK-S), 'Kommission beginnt Beratung der zweiten Etappe zur Umsetzung der Pflegeinitiative' (2 September 2026), medicine section; Eidgenössisches Departement für Wirtschaft, Bildung und Forschung (WBF) and Eidgenössisches Departement des Innern (EDI), 'Arbeitsgruppe zur Sicherstellung bestmöglicher Rahmenbedingungen für die Lifesciences in der Schweiz' (13 January 2026). The committee texts are recommendations, not enactments. On 2 September 2026 the Council of States' committee (SGK-S) unanimously recommended that the Federal Council wait for the same working group before adopting the amendments, but saw no need for fundamental revision. In its view the package Parliament adopted remained the framework, and the revision should secure access to innovative medicines while placing, as far as possible, no further burden on premium payers. Both committees asked that the differentiated review aimed at low-cost generics go ahead. Neither committee's published medicines section expressly addressed confidentiality. The working group, convened by the heads of the federal departments of economic affairs and of home affairs in January 2026, was due to report at the end of that year.

The wait does not suspend Swiss pricing. Until the relevant new provisions enter into force, the BAG prices new medicines under the existing ordinance, with its average-based foreign comparison, its three-year reviews and the existing administrative refund practice and applicable official-access exceptions. That last point has been litigated. In August 2023 the Federal Administrative Court held that the BAG's draft decision on the listing of a medicine whose holder had withdrawn its application was an official document within the meaning of Art. 5 BGÖ, and sent the case back because the BAG had not given reasons of its own on whether the business-secrets exception in Art. 7(1)(g) BGÖ covered the price and economic-efficiency data in the draft.8Bundesgesetz über das Öffentlichkeitsprinzip der Verwaltung (Öffentlichkeitsgesetz, BGÖ) vom 17. Dezember 2004 (SR 152.3), Stand am 1. November 2023, Art. 5 BGÖ (official documents) and Art. 7 Abs. 1 lit. g BGÖ (professional, business and manufacturing secrets). Urteil BVGer A-1051/2022 vom 29. August 2023, E. 6.3 (the draft decision sent to the holder for comment in the concluded SL proceeding was an official document), E. 8.1–8.2 (exceptions, proportionality and the separate privacy inquiry), E. 9.3 and E. 11 (partial-access decision set aside and remanded for inadequate reasons on business secrets and the holder's data under the law then applicable; no final ruling requiring disclosure of the disputed pricing information). The amended statute lets the Federal Council answer the question for refunds, and a transitional provision extends Art. 52c KVG to access requests still pending when it takes effect. Until then, an access request requires a case-specific assessment of the applicable exceptions and any proportionate partial access.

2. How US Most-Favored-Nation Mechanisms Use Swiss Prices

Executive Order 14297 directs the Secretary of Health and Human Services to communicate most-favored-nation price targets to manufacturers "to bring prices for American patients in line with comparably developed nations" and, if significant progress is not delivered, to propose a rulemaking plan. It also directs the Secretary of Commerce and the US Trade Representative to act against foreign practices that suppress the price of pharmaceutical products below fair market value.2 On 31 July 2025 the President wrote to seventeen manufacturers, Genentech and Novartis among them. According to the White House, the steps the letters set out included a stipulation that the companies "will not offer other developed nations better prices for new drugs than prices offered in the United States".9The White House, 'Fact Sheet: President Donald J. Trump Announces Actions to Get Americans the Best Prices in the World for Prescription Drugs' (July 31, 2025); 'Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients' (September 30, 2025); 'Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients' (December 19, 2025); and 'Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans' (August 31, 2026). Agreements followed from 30 September 2025, and by 31 August 2026 the White House counted twenty-six manufacturers with MFN agreements, covering 89 percent of the branded drug market. The fact sheets for the agreements of September 2025, December 2025 and August 2026 each describe a guarantee of MFN prices on all new innovative medicines the companies bring to market. The December 2025 fact sheet also records an agreement with the United Kingdom, announced on 1 December 2025, that the White House described as increasing the net price of new prescription drugs in the United Kingdom by 25 percent.

These fact sheets do not disclose the full agreements. They establish what the White House announced, but not the precise product coverage, price definitions, affiliate obligations, reporting rights or duration applicable to an individual manufacturer. Those questions require the agreement itself. The BAG's page on Swiss-US health topics, bearing a 24 July 2026 publication date, also describes the Federal Council's limited knowledge of the agreements, their reported focus on new medicines and their inclusion of Swiss prices alongside those of other countries.10Bundesamt für Gesundheit (BAG), “Schweiz – USA: Gesundheitsthemen” (web page dated 24 July 2026), section “US-Medikamentenpreise und Folgen für die Schweiz”: the BAG's account states that the Federal Council does not know the agreements' content in detail, describes them as concerning mainly new medicines reaching the market in coming years, and says Swiss prices are among those taken into account in the US foreign-price comparison. This is an agency account, not the agreements' contractual text. A Swiss affiliate's access to the commitment its parent signed is a matter of group governance, distinct from what the public descriptions establish.

The Centers for Medicare & Medicaid Services (CMS) published the GLOBE model for certain Part B drugs and the GUARD model for certain Part D drugs as proposed rules on 23 December 2025. GLOBE's proposed performance period would begin on 1 October 2026; GUARD's would begin on 1 January 2027. Both would use international benchmarks drawn from nineteen reference countries, including Switzerland. Neither proposal had been finalized by 3 September 2026.11Centers for Medicare & Medicaid Services, 'Global Benchmark for Efficient Drug Pricing (GLOBE) Model', proposed rule, 90 Fed. Reg. 60244 (December 23, 2025), RIN 0938-AV66; and 'Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model', proposed rule, 90 Fed. Reg. 60338 (December 23, 2025), RIN 0938-AV74. Proposed §§ 513.1(c), 513.310, 513.400–420 and 513.600–610 of the GLOBE Model proposal; proposed §§ 514.1(c), 514.210–220, 514.300–310 and 514.410 of the GUARD Model proposal.

Each proposal would establish a default from the lowest adjusted country-level price in selected commercial data and hold that default fixed once set for the drug. CMS cautioned that such data would be unlikely to capture confidential rebates, but the default is not invariably a gross list price: GLOBE expressly contemplates concessions where the selected source includes them. Both models would accept qualifying manufacturer submissions of international net prices and use the higher available benchmark. GLOBE's optional route uses quarterly data, generally with a two-quarter lag; GUARD's uses the relevant performance year's data.11

Medicaid has a separate voluntary route. CMS's GENEROUS State Request for Applications, version 1.0 of 23 December 2025, describes supplemental rebates based on the second-lowest adjusted country-specific manufacturer-reported net price in an eight-country basket that includes Switzerland. Participation depends on agreements among CMS, manufacturers and states; the RFA expressly warns that finalized participation agreements may differ from its terms. This is a distinct route for Swiss net-price information, not proof that a particular manufacturer or product is covered.12Centers for Medicare & Medicaid Services, 'GENEROUS Model (GENErating cost Reductions fOr U.S. Medicaid Model): Request for Applications from States', version 1.0, last modified December 23, 2025. Sections 1.1, 2.2 and 2.4 of the GENEROUS Model State Request for Applications, pp 3–4, 7 and 14–15.

Proclamation 11020 of 2 April 2026 created a further incentive to reach qualifying onshoring and MFN arrangements. For covered patented pharmaceuticals and associated ingredients from Switzerland and Liechtenstein, it set a 15 percent rate unless a lower applicable rate applies, including zero treatment through 20 January 2029 for qualifying companies. Its treatment began on 31 July 2026 for companies in Annex III to Proclamation 11020 but was scheduled for 29 September 2026 for other companies. Product scope and exemptions matter: generic pharmaceuticals were excluded from these duties under section 232 of the Trade Expansion Act of 1962, and certain specialty products could qualify for zero treatment under stated conditions.13Proclamation 11020 of April 2, 2026, Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States, 91 Fed. Reg. 18183 (April 9, 2026). Clauses (3)(c)–(e), (4)–(5), (7)–(8) and (11) of Proclamation 11020.

On 18 June 2026 the US Trade Representative opened an investigation under section 301 of the Trade Act of 1974 into what it called Germany's persistent underpayment for innovative pharmaceutical products, with a public hearing scheduled for 22 September 2026. The notice identifies confidentiality conditioned on an additional 9 percent discount and administrative costs, the German mechanism examined in the analysis of German confidential reimbursement.14Office of the United States Trade Representative, 'Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany’s Persistent Underpayment for Innovative Pharmaceutical Products', 91 Fed. Reg. 38072–74 (June 24, 2026), Dockets USTR-2026-0463 and USTR-2026-0464. The notice begins an investigation, not a completed adverse determination. Its objection to the conditions attached to confidentiality has an analogy in the Swiss proposal, but it does not establish a US investigation of Switzerland.

3. Does Swiss Rebate Confidentiality Hold Against a US Pricing Commitment?

Art. 52c KVG concerns third-party access to refund information; it does not by itself answer whether a holder may disclose its Swiss net price under a separate US obligation. Its first paragraph authorizes rules restricting access, and its second directs official-access refusals under the BGÖ or cantonal equivalents.5 Neither paragraph contains an express holder-specific disclosure rule, but that does not establish permission to transfer information. Art. 65bsexies(3) of the draft KVV expressly binds other holders receiving comparator data to confidentiality; it does not determine every duty the original holder may owe.6 Art. 52b(5) KVG also permits disclosure to insurers and other specified recipients only insofar as the data are necessary to claim refunds or execute the statute. These provisions distinguish restricted public access from defined information flows. They do not resolve the contractual, regulatory and criminal-law constraints on a particular US submission.

The July 2025 White House statement concerned prices offered, not merely prices published. If a manufacturer's actual agreement adopts such a commitment, Swiss confidentiality would not by itself remove the contractual obligation. The applicable price definition, product coverage and any audit, certification or reporting requirements must be read in that agreement; the public fact sheets do not establish them.9

The proposed Medicare models raise a different question. A confidential Swiss rebate could be absent from a selected commercial source, but that depends on the source and its adjustments. A qualifying manufacturer submission could include the Swiss net price and contribute to a higher international average than the fixed default. Both proposals would use the higher available benchmark, so neither the existence nor the later disclosure of a low Swiss price necessarily determines the result.11

Such submissions would provide net-price information to CMS under the relevant model requirements. The proposals protect submitted information only to the extent permitted by US law; GLOBE also reserves specified implementation disclosures. Those protections do not themselves resolve whether disclosure is permissible under Swiss law.11

Swiss criminal law raises separate questions. Art. 273 StGB covers making a protected manufacturing or business secret accessible to specified foreign recipients. Art. 271 StGB concerns unauthorized conduct on Swiss territory on behalf of a foreign state that has the character of an act reserved to an authority or official.15Schweizerisches Strafgesetzbuch (StGB) vom 21. Dezember 1937 (SR 311.0), Stand am 12. Juni 2026, Art. 271 Ziff. 1 StGB (unauthorized acts on Swiss territory for a foreign state that are reserved to an authority or official) and Art. 273 StGB (economic intelligence involving manufacturing or business secrets and specified foreign recipients). BGE 148 IV 66, Urteil 6B_216/2020 vom 1. November 2021, E. 1.4.1–1.4.3 (official character and circumvention of the assistance route when supplying third-party banking documents to the DoJ). BGE 141 IV 155, Urteil 6B_508/2014 vom 25. Februar 2015, E. 4.2.1–4.2.3 and E. 4.2.5 (protected business secrets, the required Swiss connection and overlapping interests in bank customer data). Neither judgment determines the lawfulness of a pharmaceutical-pricing submission. Whether the affiliate is legally entitled to disclose the information, whether protected interests of others are involved, and whether the transfer has that official character must be assessed separately. The Federal Supreme Court's decisions on foreign transfers of banking information illustrate those distinctions; they do not decide pharmaceutical-price reporting. Neither ownership of a price figure nor a recipient's confidentiality promise settles both offenses. The KVG and its draft ordinance do not answer those questions for a particular submission to a US agency, or expressly determine whether a Swiss confidentiality order survives the holder's disclosure of the same figure elsewhere.

The draft ordinance adds a symmetry the US reader should not miss. Art. 65bquater(1ter) of the draft KVV would let the BAG use the price actually reimbursed in a reference country, or drop that country from the comparison, where there are indications that the published foreign price differs from the amount paid, or where the holder breaches its cooperation duty by withholding effectively reimbursed foreign prices. Art. 13 VwVG governs cooperation in the application procedure, with an exception for qualifying lawyer-client materials and limits on refusing to entertain a request.16Bundesgesetz über das Verwaltungsverfahren (Verwaltungsverfahrensgesetz, VwVG) vom 20. Dezember 1968 (SR 172.021), Stand am 1. Juli 2022, Art. 13(1)(a) VwVG (cooperation in applicant-initiated proceedings), Art. 13(1bis) VwVG (qualifying lawyer-client materials excepted) and Art. 13(2) VwVG (refusal to entertain a request where necessary and reasonable cooperation is withheld). Switzerland would ask the holder for the confidential net prices of other countries while offering to hide its own. The United States asks its manufacturers for their foreign net prices, voluntarily in the Medicare proposals, while federal law generally protects the Medicaid price data they report, subject to statutory exceptions.1 The group can therefore face different demands for price information on each side. Public-access protection, a reporting obligation and permission to disclose are separate questions.

4. Can the Federal Council Hold Back What Parliament Enacted?

The amending act gives the Federal Council responsibility for commencement. Section V of the KVG amendment sets no date by which the medicines provisions must take effect.5 The committees had been consulted on the drafts; Art. 151 ParlG provides for consultation of competent committees on important Federal Council ordinances.17Bundesgesetz über die Bundesversammlung (Parlamentsgesetz, ParlG) vom 13. Dezember 2002 (SR 171.10), Stand am 2. März 2026, Art. 151(1)–(2) ParlG (consultation of competent parliamentary committees on important Federal Council ordinances; the committee decides during the overall vote on the parliamentary bill whether it wishes to be consulted on an immediately following ordinance). Their recommendations do not themselves adopt or veto the ordinance. The two committees agreed on waiting but disagreed on the extent of subsequent revision.7 That leaves an implementation choice within the statute, rather than an independent power to replace the parliamentary decision or disregard it indefinitely.

The rebates themselves are not self-executing. Art. 52b KVG says the BAG may require refunds, and only by way of exception. Art. 52e KVG says the holder may be obliged to compensate, at listing or at the next review, and leaves the details to the Federal Council, and Art. 52d KVG leaves the implementing provisions to it as well.5 The statute does not set the cost-consequence threshold or rate bands. The CHF 15 million threshold and the rates of up to 40 percent exist only in the draft KVV and KLV, and the explanatory report itself calls the rates provisional, to be fixed definitively by a later amendment.6 An ordinance that defers them is not deferring a rebate the statute sets. It is deferring the only text that would set one.

The question has a harder edge than form. Parliament did not only authorize the cost-consequence model. It wrote transitional rules around it. Products listed before commencement are exempt from Art. 52e KVG for two years to the extent of the turnover they achieved before the rule took effect, and the BAG must report, within four years after that period ends, on the model's savings, on access to new medicines and on delays in filing with Swissmedic and in market access.5 The legislature anticipated that the model might slow filings and told the administration to measure the effect. A committee that asks the Federal Council to reshape the model around a foreign reference-price system asks for something the statute neither requires nor forbids, and the evaluation clause suggests that Parliament was aware of the trade-off when it adopted the text. Whether a reshaping that changes who pays, and how much, still implements the statute Parliament passed, or begins to replace it, is a line the text does not draw.

For a US originator the wait has a practical content that is easy to misread. The existing pricing rules govern until the relevant amendments take effect, but filing earlier would not by itself preserve that method for a later decision. Transitional provision VII(1) of the February draft KVV would apply the new rules to proceedings pending at the BAG when the amendment enters into force. Adoption and commencement are distinct, and the draft leaves the commencement date blank. Products already on the SL are treated separately by VII(2): the cost-consequence model would first be examined at the next review of admission conditions, no earlier than two years after commencement, with special treatment of the preceding turnover and subsequent growth.6 The eventual ordinance, the proceeding's status and the medicine's existing listed status therefore matter more than the filing date alone. The final transition remains subject to the ordinance adopted.

The provisional list under Art. 52d KVG raises a further point for a US originator. Admission is discretionary and subject to the statutory conditions, rather than automatic on accelerated authorization. The draft provides for publication of the provisional list and price.6 If the definitive economical price is lower, the holder must refund the excess turnover; a provisional price set too low can instead lead to compensation after definitive listing. Art. 52d(5) KVG excludes information on the difference, the refunded turnover and connected information from public-access laws. If the holder withdraws the definitive application or the BAG rejects it, the BAG may disclose the application and last reimbursed price to the recipients in Art. 52b(5) KVG. Subsequent single-case reimbursement is conditional, capped at five years and subject to further pricing rules; the provisional price is a maximum, not a guaranteed reimbursement amount.5 A published provisional price might matter to a US commitment or data source before the definitive Swiss price exists, but that depends on the relevant mechanism and its treatment of the product and price.

5. For US Originators Deciding Whether to Seek Swiss Reimbursement

The decision Interpharma's members reported is a decision not to ask. Swiss reimbursement is application-driven, and the explanatory report states that listing is not automatic.6 A medicine authorized by Swissmedic but absent from the SL may qualify for single-case reimbursement under Art. 71b KVV where a condition in Art. 71a(1) KVV is met. One route requires expected high therapeutic benefit against a disease that may be fatal or cause severe and chronic harm, where no other effective and authorized treatment is available because therapeutic alternatives are lacking. The insurer must give special approval after consulting its medical adviser. It fixes reimbursement after consulting the holder, using the foreign-price comparison subject to the prescribed discounts and exceptions. For an imported medicine without Swissmedic authorization, Art. 71c KVV additionally requires lawful import under the HMG and authorization for the indication in a country whose authorization system Swissmedic recognizes as equivalent.4 These routes do not assure coverage merely because a product is absent from the SL. Whether a separately agreed insurer price falls within a group's US undertaking, or enters a particular commercial database, depends on its terms and data coverage. Interpharma's warning of unequal patient access concerns that difference between ordinary listing and a physician's application for an individual reimbursement decision.3

The decision to file, or to wait, also leaves a record. An application withdrawn after the BAG has prepared its draft decision leaves an official document behind, as the Federal Administrative Court held in 2023,8 and under the amended statute the withdrawal of an application for definitive listing of a provisionally reimbursed medicine lets the BAG tell the insurers the last reimbursed price.5 A company that files to learn what the BAG would offer, and withdraws when it has learned, may find that the offer outlives the application. How long a Swiss affiliate can defer a filing before the delay itself becomes the issue, for patients, for the statutory evaluation of filing delays and for the Parliament that commissioned it, is a judgment the group has to make without knowing which ordinance will apply.

The horizons do not align. The Swiss draft's confidentiality period runs for six years from medicine or indication listing and can be extended only exceptionally.6 Qualifying tariff relief lasts through 20 January 2029.13 GLOBE's proposed performance period would end on 30 September 2031 and GUARD's on 31 December 2031; their payment periods would extend into 2033. That later payment activity does not mean the fixed defaults would keep absorbing new Swiss prices.11 The timing of optional submissions and the duration and terms of the manufacturer's actual agreement must be assessed separately.

For a parent whose disclosures are governed by Regulation S-K, the Swiss decision also has a disclosure dimension. A pattern of non-filing in a market that its own agreement treats as a reference, a Swiss price that turns out to set a US benchmark, or a section 301 action of the kind the US Trade Representative has opened against Germany14 may each become one of the material factors that make an investment speculative or risky within Item 105 of Regulation S-K.1817 C.F.R. § 229.105(a)–(b), Item 105 of Regulation S-K (Risk factors): material risks and their effect on the registrant or securities. The governance question is who in the group decides the Swiss price with that in view. The Swiss affiliate that negotiates with the BAG is the Swiss holder, answerable to Swiss authorities, the applicant for any Swiss confidentiality order and within the reach of Swiss criminal law; the entity that signed the US agreement may sit elsewhere in the group. Whether the two have compared what each has undertaken is a question with a documentary answer.

The Swiss filing decision connects a product's indications and turnover with the group's US commitments, the applicable price-data rules and the timing of two different regulatory systems. The proposed Swiss confidentiality order does not settle those other questions. Nor can public announcements establish the terms an affiliate has accepted or the information it is legally entitled to disclose.